TRPM7 regulates the migration of human nasopharyngeal carcinoma cell by mediating Ca2+ influx
Jianpeng Chen(Northeastern University), Rong Li(Nanfang Hospital), Yi Luan, Xiaohua Chen(Kunming University of Science and Technology), Changxuan You(Southern Medical University), Rongcheng Luo(Hebei Medical University)
Cited by 135
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients
|Biomedicine & Pharmacotherapy|2015|126
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
|Annals of Oncology|2013|120
MiR‐219‐5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican‐3
|FEBS Letters|2012|102